MedMinder Pro - Medication Adherence Coach

Model: qwen/qwen3-max
Status: Completed
Cost: $0.457
Tokens: 121,237
Started: 2026-01-05 14:38

Business Model & Economics

✅ Dual-Stream Revenue Model: B2C + B2B

LTV:CAC = 12:1 with break-even at 210 customers by Month 7

Revenue Model Overview

Primary Revenue Streams:

B2B Health Plan Licensing (65% of revenue)
Model Type: Per Member Per Month (PMPM)
Rationale: Health plans face $300B in annual costs from non-adherence and operate under value-based contracts that penalize poor outcomes. At $2-5 PMPM for high-risk members, MedMinder Pro delivers measurable ROI through reduced hospitalizations and ER visits. This model provides predictable, scalable revenue with lower churn than consumer subscriptions.
Consumer Freemium (25% of revenue)
Model Type: Subscription + Usage-based
Rationale: Direct-to-consumer model builds user base, validates product-market fit, and creates data flywheel for ML improvements. The $4.99/month price point is accessible for seniors while capturing value from those managing complex regimens. Free tier drives viral adoption through caregiver networks.
Pharma/Pharmacy Partnerships (10% of revenue)
Model Type: Licensing + Success fees
Rationale: Specialty pharmaceutical companies spend billions on adherence programs with limited effectiveness. Our AI-driven approach provides superior outcomes, justifying premium pricing for adherence programs targeting specific high-value medications.

Revenue Model Evolution

  • Year 1: Consumer freemium focus (70%) + early B2B pilots (30%)
  • Year 2-3: B2B health plan licensing (65%) + consumer (25%) + pharma partnerships (10%)
  • Maturity: B2B dominant (75%) with consumer as acquisition channel and pharma as strategic premium stream (15%)

Pricing Strategy & Tier Structure

Tier Target User Price Key Features Conversion Goal
Free Basic medication users $0/mo 5 medications, basic reminders, simple adherence tracking 8% → Paid
Premium Complex regimen patients, caregivers $4.99/mo Unlimited meds, caregiver dashboard, pharmacy integration, root cause insights 65% retention
Family Plan Adult children managing parents $7.99/mo Premium features for 3 family members, shared dashboard, emergency alerts 40% of paid

Market Benchmark Comparison

Competitor Entry Price Mid Tier Your Position
Medisafe $4.99/mo $9.99/mo Feature parity, better value
Mango Health Free $2.99/mo Superior intelligence
MedMinder Pro $0-4.99 $7.99/mo AI-powered differentiation

Customer Acquisition Economics

Channel Monthly Spend Conversions CAC Notes
Facebook/Instagram Ads $3,000 45 $67 Targeting 50+ demographics
Google Search $2,000 25 $80 High intent keywords
Pharmacy Partnerships $1,500 30 $50 In-pharmacy promotions
Referral Program $500 20 $25 Caregiver network effects
Total $7,000 120 $58 Blended CAC

Lifetime Value (LTV) Analysis

ARPU Breakdown

Premium: $4.99 × 70% = $3.49

Family Plan: $7.99 × 30% = $2.40

Blended ARPU: $5.89

Retention Metrics

Monthly Churn: 4.2%

Annual Retention: 60%

Avg. Lifetime: 24 months

LTV Calculation

LTV = $5.89 × 80% × (1/0.042)

LTV = $696

LTV:CAC = 12:1 ✅

Cost Structure & Margins

Fixed Costs (Monthly)

Founder Salaries $8,000
Software/Tools $800
Compliance/Legal $500
Total Fixed $9,300

Variable Costs per User

Cloud Hosting $1.20
AI API Costs $2.50
Payment Processing $0.18
Total Variable $3.88
Gross Margin = ($5.89 - $3.88) / $5.89 = 34.1%
Note: B2B health plan revenue (65% of total) has 85%+ gross margin, bringing blended margin to 72%

Break-Even Analysis

Break-Even Calculation:

Break-Even = Fixed Costs / (ARPU - Variable Costs) = $9,300 / ($5.89 - $3.88) = 210 paying customers

Break-Even Timeline

Scenario New Customers/Month Break-Even Month
Conservative 25 Month 9
Base Case 35 Month 7
Optimistic 50 Month 5

3-Year Financial Projections

Metric Year 1 Year 2 Year 3
Customers
Paying Customers 500 1,800 4,500
Revenue
ARR $352,800 $1,270,080 $3,175,200
Profitability
Net Profit $84,672 $889,056 $2,381,400
Net Margin 24% 70% 75%

Unit Economics Summary Dashboard

ARPU (Monthly):
$5.89
Gross Margin:
72%
LTV:
$696
CAC:
$58
LTV:CAC:
12:1 ✅
Break-Even:
Month 7

Funding Strategy & Use of Funds

Seed Funding Path: $750K seed round provides 18-month runway with focus on B2B health plan acquisition and product development.

Category Amount % Purpose
Engineering $400K 53% 2.5 FTE for 18 months
Clinical/Regulatory $75K 10% HIPAA compliance, FDA guidance
Infrastructure $100K 13% Cloud, security, compliance
Marketing/Pilots $175K 23% Health plan pilots, pharmacy partnerships

Business Model Risks & Mitigations

🔴 High Risk: Health Plan Sales Cycle Length

Health plan procurement cycles average 9-18 months, creating cash flow pressure during early growth. Revenue concentration in few large customers increases dependency risk.

Mitigation: Pursue pharmacy chain partnerships as faster B2B2C channel while building health plan pipeline. Develop compelling ROI calculator showing $3.20 return per $1 spent based on industry adherence improvement data.

🟡 Medium Risk: AI API Cost Volatility

Reliance on third-party AI APIs creates exposure to pricing changes that could erode margins, especially if usage scales faster than anticipated.

Mitigation: Implement usage caps and caching strategies. Develop proprietary lightweight models for common adherence patterns. Negotiate volume-based pricing tiers with multiple AI providers to maintain leverage.

🟡 Medium Risk: Consumer Price Sensitivity

Target demographic (50+ on fixed incomes) may resist subscription pricing despite clear value proposition, limiting consumer revenue potential.

Mitigation: Position premium features as cost-saving (pharmacy price comparison, coupon discovery). Offer annual billing at 20% discount. Focus consumer acquisition on adult children managing parents who have higher willingness to pay.

Alternative Business Models Considered

Alternative #1: Pure B2B SaaS Model
Pros: Higher ACV, lower churn, predictable revenue
Cons: Longer sales cycles, limited market validation speed, higher customer concentration risk
Rejection Reason: Consumer freemium provides essential user feedback, data for ML training, and creates viral acquisition through caregiver networks that accelerate B2B sales.
Alternative #2: Transaction-Based with Pharmacies
Pros: Revenue tied to actual medication purchases, strong pharmacy partnerships
Cons: Complex revenue attribution, regulatory complexity, lower margins
Rejection Reason: PMPM model aligns better with health plan incentives and provides more predictable revenue stream essential for startup scaling.

Why Current Model is Best: The dual-stream approach leverages consumer adoption to build product validation and data assets while pursuing high-margin B2B contracts. This hybrid model de-risks the business by providing multiple revenue pathways and accelerates market penetration through network effects between patients, caregivers, and healthcare providers.